Browsing Tag
CSL Limited
8 posts
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
ASX healthcare sector falls harder than the broader market as rate shock and Middle East war pressure high-multiple stocks
ASX healthcare stocks fell 2.47% on 19 March, lagging every other defensive sector. Here's what's driving CSL, Pro Medicus and Cochlear lower. Read more.
CSL (ASX:CSL) breaks ground on $1.5bn Kankakee plasma plant expansion, betting patented Horizon 2 technology can widen its immunoglobulin lead
CSL (ASX:CSL) breaks ground on a $1.5B Kankakee plasma plant expansion using patented Horizon 2 yield tech. Read the full strategic analysis.
Five-year durability data show Hemgenix is transforming haemophilia B care with a single dose
Five‑year results show Hemgenix delivers long‑lasting bleed protection and stable clotting factor levels for haemophilia B patients. Read more on the breakthrough here.
CSL Seqirus data show cell-based flu vaccine provides 20% stronger protection against lab-confirmed influenza
Find out how CSL Seqirus’s real-world data reveal a 20% protection boost for its cell-based flu vaccine over traditional egg-based shots.
Nyrada Inc (ASX: NYR) stock draws fresh attention as investors eye trial milestones in 2025
Nyrada Inc (ASX: NYR) stock is moving on higher volumes as trial milestones near. Find out why investors are watching this biotech in 2025.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.
CSL Limited’s AEGIS-II trial of CSL112 fails to meet primary endpoint in heart attack patients
CSL Limited (ASX:CSL; USOTC:CSLLY), a renowned global biotechnology leader, disclosed the top-line outcomes from its eagerly anticipated Phase…